Evaluation of the Photorefraction Screener Snapsight in Comparison With Cycloplegia Table-top Autorefractor in Ametropia in Pediatric Population Between 3 and 8yo, Multicenter French Study.
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o. The main objectives of the study are: * Evaluate the performances of the device in comparison with the gold standard, i.e. a tabletop refractometer. * Assess the agreement of the measures obtained with the device with those obtained with the gold standard.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 8
Healthy Volunteers: t
View:
• Aged between 3-8 years when included in the study
• All skin phototypes (I to VI according to the Fitzpatrick classification)
• Wearing glasses or not
• Capacity to give valid consent
• Capacity to follow the protocol to obtain reliable measure
• Under French medical insurance
Locations
Other Locations
France
Dr Krafft private practice
NOT_YET_RECRUITING
Nancy
Hôpital civil de Strasbourg
RECRUITING
Strasbourg
Contact Information
Primary
Sara Cadoni
cadonis@essilor.fr
+33 642665760
Time Frame
Start Date: 2025-04
Estimated Completion Date: 2025-12
Participants
Target number of participants: 315
Treatments
Experimental: Snapsight photorefraction device
Related Therapeutic Areas
Sponsors
Leads: Essilor International